Steroid-dependent asthma treated with inhaled beclomethasone dipropionate. A long-term study.
The efficacy of inhaled beclomethasone dipropionate has been examined in 44 steroid-dependent asthmatics observed for 9 months to 2 years. A 3-month double-blind trial found that subjects treated with beclomethasone had a significant diminution in symptoms, were able to reduce their use of medication, and had improved maximum expiratory flow rates. Approximately one half were able to discontinue the use of oral prednisone within 9 months after starting beclomethasone, and a further one third reduced their dose by at least 50%. No characteristics could be defined to predict responsiveness to beclomethasone. The effectiveness of beclomethasone was sustained for as long as 2 years and was not associated with any abnormal urine, blood, or serum values or chest X-ray findings. Candidiasis of the palate appeared in approximately one third of the subjects and was usually transient. The chronic use of beclomethasone did not result in endocrine suppression.
D000284:Administration, Oral; D000336:Aerosols; D000900:Anti-Bacterial Agents / Q000009:adverse effects; D001249:Asthma / Q000188:drug therapy*; D001507:Beclomethasone / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D002177:Candidiasis / Q000139:chemically induced; D002986:Clinical Trials as Topic; D005541:Forced Expiratory Volume; D006801:Humans; D010919:Placebos; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use*; D019966:Substance-Related Disorders; D014797:Vital Capacity
D000336:Aerosols; D000900:Anti-Bacterial Agents; D010919:Placebos; D001507:Beclomethasone; D011241:Prednisone